Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1988-07-29
1989-10-17
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31135
Patent
active
048747939
ABSTRACT:
This invention discloses the use of a dibenzo cycloheptene deriative, generally known as protriptyline for the treatment of mental health problems in children, specifically Attention Deficit Syndrome or Attention Deficit Disorder. By administering the correct dosage of this drug, children have shown improved concentration, improved sleep patterns, less behavioral problems both in school and at home and an overall improvement in the child behavior. This new use for protriptyline is unexpected and is contraindicated in the literature since protriptyline has commonly been used only as a antidepressant for adults and not as a mild stimulant in the treatment of childhood mental health problems, such as Attention Deficit Disorder or Syndrome.
REFERENCES:
patent: 3244748 (1966-05-01), Tishler et al.
patent: 3271451 (1966-09-01), Tishler et al.
patent: 3324170 (1967-06-01), Kollonitsch
patent: 3372196 (1968-05-01), Engelhardt
patent: 3445519 (1969-05-01), Kollonitsch
patent: 3513201 (1970-05-01), Tishler et al.
patent: 3922305 (1975-11-01), Engelhardt
patent: 4136116 (1979-01-01), Kyburz
Diagnostic and Statistical Manual of Mental Health Disorders pp. 43-44 (1980) American Psychiatric Association.
Physicians Desk Reference, Barnhart pp. 1349-1350 (1987)-(will be provided).
Dorfman, W. The use of Protriptyline (MK-20). As a Antidepressant; A Preliminary Report; Am. J. Psych. 126(594-595), (1963).
Vaisberg, M., Protriptyne in the Treatment of Depressive States, Dis. Nerv. Syst. 25 110-111, (1964).
Oltman & Friedman, Protriptyline in the Treatment of Depressive Reactions, Am. J. Psych. 122, 582-584, (1965).
Krakowski, Protriptyline in Treatment of Severe Depressions; A Long Range Pilot Study, Am. J. Psych. 121, (807-809), (1965).
Weinstock, R. et al., Effects of Protriptyline and Perphenazine in Neurotic Depressed Outpatients, J. Clin. Phar. 627-630, (1975).
Whyte, et al., Plasma Concentrations of Protriptyline and Clinical Effects in Depressed Women, Brit. J. Psych. 128, 384-390, (1976).
Kashani & Contwell, Etiology and Treatment of Childhood Depression: A Biopsychological Perspective; Child Psych. & Hum. Dev. 23(3), 348-351, (1984).
Coilbert, M. & Koepke, H. Oxazepam Protriptyline: A double-blind Phase II Evaluation of the Efficacy and Safety of the Combination Versus Placebain Neurotic, Depressed and Anxious Psychiatric Outpatients, Current Therapeutic Res. 18, No. 6, 825-838, (1975).
USP DI, 7th Ed. (1987), vol. 1, pp. 244-246, and 251-252.
MSD, Vivactil (Protriptyline HCL) package insert, issued Jul. 1986.
Cox Scott R.
Friedman Stanley J.
Kearse Richard M.
LandOfFree
Use of protriptyline for the treatment of mental health problems does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of protriptyline for the treatment of mental health problems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of protriptyline for the treatment of mental health problems will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1743971